外周血中TAP含量预测Her-2阳性乳腺癌新辅助化疗疗效价值的研究

The Value of TAP Content in Peripheral Blood in Predicting the Efficacy of Neoadjuvant Chemotherapy for Her-2 Positive Breast Cancer

目的探讨外周血中肿瘤异常糖链蛋白(tumor abmormal protem,TAP)水平变化在Her-2阳性乳腺癌病人新辅助化疗的化疗效果评价等方面是否具有一定的预测意义。方法对采用乳腺癌新辅助化疗TCbHP方案治疗的117例Her-2阳性的乳腺癌病人,进行了回顾性分析与研究。按照术后病理结果进行分组,分为pCR组和non pCR组,所有入组的患者在接受第1周期和第3周期新辅助化疗开始前均接受外周血TAP检测,观察TAP值的变化能否预测新辅助化疗疗效。结果相比于第1周期化疗前的TAP值,第3周期新辅助化疗前的TAP值有着明显的降低,两周期化疗前的TAP值做差后发现pCR组的TAP差值要明显高于non pCR组,具有统计学意义(P<0.05)。ROC曲线证实第1周期和第3周期新辅助化疗前TAP差值高于40.9μm2以上的Her-2阳性乳腺癌患者更容易达到pCR。结论达到pCR组患者的TAP下降值显著高于non pCR组,可能对于Her-2阳性乳腺癌患者接受新辅助化疗(TCbHP方案)疗效评估具有一定的预测价值。

Objective To investigate whether the level of TAP(tumor abnormal protein)in peripheral blood has a certain predictive significance in evaluating the efficacy of neoadjuvant chemotherapy in patients with Her-2 positive breast cancer.Methods 117 breast cancer patients with positive Her-2 were treated with neoadjuvant chemotherapy TCbHP.According to the postoperative pathological results,the patients were divided into pCR group(pathological complete response)and non-pCR group(non-pathological complete response).All the enrolled patients received peripheral blood TAP test before the first cycle and the third cycle of neoadjuvant chemotherapy to observe whether the change of TAP value can predict the efficacy of neoadjuvant chemotherapy.Results Compared with the TAP value before the first cycle of chemotherapy,the TAP value before the third cycle of neoadjuvant chemotherapy was significantly reduced.After the difference between the TAP values before the two cycles of chemotherapy,it was found that the TAP difference of the pCR group was significantly higher than that of the non-pCR group,with statistical significance(P<0.05).ROC curve confirmed that Her-2 positive breast cancer patients with TAP difference higher than 40.9μm~2 before the first cycle and the third cycle of neoadjuvant chemotherapy were more likely to achieve pCR.Conclusion The TAP decrease value of patients in the pCR group was significantly higher than that in the non-pCR group,which may have a certain predictive value for the efficacy evaluation of neoadjuvant chemotherapy(TCbHP regimen)in patients with Her-2 positive breast cancer.